ArticleNature communications2021
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 48 citations in OpenAlex.
- Exploring copy number alterations (CNAs) to gain new insight into SCLC heterogeneity.Molecular biology reports · 2026Review
- Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges.Journal of nanobiotechnology · 2026Review
- Association of copy number alterations with the immune transcriptomic landscape in cancer.NPJ systems biology and applications · 2026Article
- Evaluating the prognostic value of mutational signatures in small-cell lung cancer through reference-based signature assignment and continuous activity analysis.Frontiers in genetics · 2026Article
- Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies.Frontiers in oncology · 2026Review
- Pan-cancer bone metastasis atlas at single-cell resolution identifies a distinct tumor-associated macrophage subset for mediating Denosumab-induced immunosensitization in lung cancer bone metastasis.International journal of biological sciences · 2026Article
- Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer.Molecular cancer · 2025Article
- Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy.Immuno-oncology technology · 2025Review
- Immunogenomic analysis of concurrent lung cancer and tuberculosis reveals distinct immune milieu.Molecular biomedicine · 2025Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- The current and emerging immunotherapy paradigm in small-cell lung cancer.Nature cancer · 2025Review
- LTF as a Potential Predictive Biomarker for Durable Benefit From First-Line Chemo-Immunotherapy in Small Cell Lung Cancer.Cancer science · 2025Article
- Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.Nature reviews. Clinical oncology · 2025Review
- A prognostic model of 8-T/B cell receptor-related signatures for hepatocellular carcinoma.Discover oncology · 2025Article
- Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer.Cell reports. Medicine · 2024Article
- Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel.JTO clinical and research reports · 2024Article
- Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer.Cell discovery · 2024Article
- Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes.Cancer innovation · 2024Article
- Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The genomic landscape of the immune system in lung cancer: present insights and continuing investigations.Frontiers in genetics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 8 institutions in 5 countries.
Ming Chen *Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China. chenming@sysucc.org.cn.
Runzhe Chen *Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Ying Jin *The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China.
Jun Li *Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Xin Hu *Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Jiexin Zhang *Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-9526-6730
Junya FujimotoDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Shawna M HubertDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0002-7907-9609
Carl M GayDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0002-4907-0718
Bo ZhuDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Yanhua TianDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Nicholas McGranahanCancer Research United Kingdom-University College London Lung Cancer Centre of Excellence, London, WC1E6BT, UK.ORCID http://orcid.org/0000-0001-9537-4045
Won-Chul LeeDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Julie GeorgeDepartment of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany.ORCID http://orcid.org/0000-0002-4272-3683
Xiao HuThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China.
Yamei ChenThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China.
Meijuan WuThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China.
Carmen BehrensDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Chi-Wan ChowDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Hoa H N PhamDepartment of Pathology, Nagasaki University Graduate school of Biomedical Sciences, Nagasaki, Japan.ORCID http://orcid.org/0000-0002-0998-4486
Junya FukuokaDepartment of Pathology, Nagasaki University Graduate school of Biomedical Sciences, Nagasaki, Japan.
Jia WuDepartment of Image Physics, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-8392-8338
Edwin Roger ParraDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-9068-1636
Latasha D LittleDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Curtis GumbsDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Xingzhi SongDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Chang-Jiun WuDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-8350-6397
Lixia DiaoDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-6995-4492
Qi WangDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0003-0858-9393
Robert CardnellDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Jianhua ZhangDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-5412-9860
Jing WangDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0002-5398-0802
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0002-8554-1185
Don L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0003-2362-3094
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-9068-8942
J Jack LeeDepartment of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-5469-9214
William N WilliamDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Chao ChengInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0002-5002-3417
Bonnie GlissonDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Ignacio WistubaDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
P Andrew FutrealDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.ORCID http://orcid.org/0000-0001-8663-2671
Roman K ThomasDepartment of Translational Genomics, Medical Faculty, University of Cologne, Cologne, 50931, Germany. roman.thomas@uni-koeln.de.
Alexandre ReubenDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. areuben@mdanderson.org.ORCID http://orcid.org/0000-0003-4510-0382
Lauren A ByersDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. lbyers@mdanderson.org.ORCID http://orcid.org/0000-0002-0780-2677
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. jzhang20@mdanderson.org.ORCID http://orcid.org/0000-0001-7872-3477
The University of Texas MD Anderson Cancer Center · USChinese Academy of Sciences · CNNagasaki University · JPBaylor College of Medicine · USCRUK Lung Cancer Centre of Excellence · GBGerman Cancer Research Center · DESun Yat-sen University · CNUniversity of Cologne · DE
Funding
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MTherapeutic strategies for targeting PARP1 in small cell lung cancerR01CA207295 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Lauren Averett Byers · 2016 to 2026
$3.7MNovel therapeutic approaches for enhancing anti-tumor immunity in SCLCU01CA213273 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2017 to 2021
$3.0MMolecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic responseU01CA256780 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2021 to 2025
$3.0MNCI NIH HHS P50 CA070907NCI NIH HHS R01 CA207295NCI NIH HHS T32 CA009302NCI NIH HHS T32 CA009666NCI NIH HHS U01 CA213273NCI NIH HHS U01 CA256780
Abstract
Small-cell lung cancer (SCLC) is speculated to harbor complex genomic intratumor heterogeneity (ITH) associated with high recurrence rate and suboptimal response to immunotherapy. Here, using multi-region whole exome/T cell receptor (TCR) sequencing as well as immunohistochemistry, we reveal a rather homogeneous mutational landscape but extremely cold and heterogeneous TCR repertoire in limited-stage SCLC tumors (LS-SCLCs). Compared to localized non-small cell lung cancers, LS-SCLCs have similar predicted neoantigen burden and genomic ITH, but significantly colder and more heterogeneous TCR repertoire associated with higher chromosomal copy number aberration (CNA) burden. Furthermore, copy number loss of IFN-γ pathway genes is frequently observed and positively correlates with CNA burden. Higher mutational burden, higher T cell infiltration and positive PD-L1 expression are associated with longer overall survival (OS), while higher CNA burden is associated with shorter OS in patients with LS-SCLC.
Indexed as
AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDNA Copy Number VariationsExome SequencingFemaleGenetic HeterogeneityHLA AntigensHumansInterferon-gammaLoss of HeterozygosityLung NeoplasmsMaleMiddle AgedMutationHLA AntigensIFNG protein, humanInterferon-gammaReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.